{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:26:08Z","timestamp":1793622368456,"version":"4.5.0"},"reference-count":110,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Taiho Oncology, Inc","id":[{"id":"https:\/\/ror.org\/02z43nn16","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,11,2]]},"DOI":"10.1080\/14737140.2026.2705531","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T18:34:18Z","timestamp":1784313258000},"page":"1447-1461","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["The burden of acute myeloid leukemia: an integrated review of clinical, economic, and patient-centered evidence"],"prefix":"10.1080","volume":"26","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[{"name":"Yale School of Medicine and Yale Cancer Center","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Taiho Oncology, Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Christensen","sequence":"additional","affiliation":[{"name":"Taiho Oncology, Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janan","family":"Amin","sequence":"additional","affiliation":[{"name":"Taiho Oncology, Inc","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0546-7895","authenticated-orcid":false,"given":"Thomas W.","family":"LeBlanc","sequence":"additional","affiliation":[{"name":"Duke University School of Medicine","place":["Durham, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00649-y"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S187409"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177783"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024944"},{"issue":"3","key":"e_1_3_5_7_1","first-page":"38","article-title":"Acute myeloid leukemia: a review","volume":"103","author":"Pelcovits A","year":"2020","unstructured":"Pelcovits A, Niroula R. Acute myeloid leukemia: a review. R I Med J. 2020;103(3):38\u201340.","journal-title":"R I Med J"},{"key":"e_1_3_5_8_1","unstructured":"National Cancer Institute. Incidence and mortality 2025 [updated 2 December 2025;7 July 2025]. Available from: https:\/\/training.seer.cancer.gov\/hematopoietic1\/incidence.html"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1115041"},{"key":"e_1_3_5_10_1","unstructured":"National Cancer Institute. Acute myeloid leukemia treatment (PDQ\u00ae)\u2013health professional version. Bethesda (MD): US Department of Health and Human Services; 2025 [cited 2025 Apr 4]. Available from: https:\/\/www.cancer.gov\/types\/leukemia\/hp\/adult-aml-treatment-pdq"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.36255\/exon-publications-leukemia-secondary-acute-myeloid-leukemia"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_199519"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/life14030309"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01099-7"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.006"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.50"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1406184"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2015.05.009"},{"key":"e_1_3_5_20_1","unstructured":"Vakiti A Reynolds S Mewawalla P. Acute myeloid leukemia treasure island. FL: StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507875\/"},{"key":"e_1_3_5_21_1","unstructured":"American Cancer Society. Signs and symptoms of acute myeloid leukemia (AML). Cancer.org: American Cancer Society; 2024. Available from: https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/detection-diagnosis-staging\/signs-symptoms.html"},{"issue":"2","key":"e_1_3_5_22_1","first-page":"62","article-title":"Acute myeloid leukemia: a focus on risk factors, clinical presentation, diagnosis and possible lines of management","volume":"5","author":"Kabel A","year":"2017","unstructured":"Kabel A, Zamzami F, Al-Talhi M, et al. Acute myeloid leukemia: a focus on risk factors, clinical presentation, diagnosis and possible lines of management. J Can Res Trt. 2017;5(2):62\u201367.","journal-title":"J Can Res Trt"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29090491"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00200-9"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017808"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2360536"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2020.19220"},{"issue":"16","key":"e_1_3_5_28_1","first-page":"S347","article-title":"Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia","volume":"24","author":"Wiese M","year":"2018","unstructured":"Wiese M, Daver N. Unmet clinical needs and economic burden of disease in the treatment landscape of acute myeloid leukemia. Am J Manag Care. 2018;24(16 Suppl):S347\u2013s355.","journal-title":"Am J Manag Care"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.07.005"},{"issue":"4","key":"e_1_3_5_30_1","first-page":"325","article-title":"A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia","volume":"11","author":"Oliva EN","year":"2021","unstructured":"Oliva EN, Ronnebaum SM, Zaidi O, et al. A systematic literature review of disease burden and clinical efficacy for patients with relapsed or refractory acute myeloid leukemia. Am J Blood Res. 2021;11(4):325\u2013360.","journal-title":"Am J Blood Res"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-016-0039-6"},{"key":"e_1_3_5_32_1","unstructured":"National Cancer Institute. Cancer Stat Facts: Leukemia \u2014 Acute Myeloid Leukemia (AML). 2025. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html"},{"key":"e_1_3_5_33_1","unstructured":"SEER*Explorer. An interactive website for SEER cancer statistics. Surveillance research program National cancer Institute. 2023 Apr 19. [updated: 2023 Jun 8]. Data source(s): SEER Incidence Data November 2022 Submission (1975\u20132020) SEER 22 registries [23 Aug 2023]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/"},{"key":"e_1_3_5_34_1","unstructured":"National Cancer Institute. Acute myeloid leukemia (AML) long-term trends in SEER age-adjusted incidence rates 1975\u20132022. 2026 [2026 March 17]. Available from: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html?site=96&data_type=1&graph_type=1&compareBy=sex&chk_sex_3=3&chk_sex_2=2&rate_type=2&race=1&age_range=1&advopt_precision=1&advopt_show_ci=on#resultsRegion1"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02435-z"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012830"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-14-0963"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014127"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/2819372"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02172-3"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.21037\/ace-23-4"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33458"},{"key":"e_1_3_5_43_1","unstructured":"National Cancer Institute. Registry groupings in SEER data and statistics 2026. Available from: http:\/\/seer.cancer.gov\/registries\/terms.html"},{"key":"e_1_3_5_44_1","unstructured":"National Cancer Institute. U.S. Mortality data 1969\u20132023. 2026. Available from: https:\/\/seer.cancer.gov\/registries\/terms.html"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2016.1112735"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.15994"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1751609"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2012666"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107353"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0706"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2024-0196"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001728"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32439"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.2016"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-181909"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2017.0463"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2024.2311305"},{"key":"e_1_3_5_58_1","unstructured":"American Cancer Society. Typical treatment of acute myeloid leukemia (except APL). 2026. Available from: https:\/\/www.cancer.org\/cancer\/types\/acute-myeloid-leukemia\/treating\/typical-treatment-of-aml.html#:~:text=People%20usually%20need%20to%20stay low%20for%20a%20few%20weeks"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07565-7"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6351"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2018.06.010"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0449-1"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30982"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02810"},{"issue":"4","key":"e_1_3_5_65_1","first-page":"1006","article-title":"Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens","volume":"108","author":"Jensen CE","year":"2023","unstructured":"Jensen CE, Heiling HM, Beke KE, et al. Time spent at home among older adults with acute myeloid leukemia receiving azacitidine- or venetoclax-based regimens. Haematologica. 2023;108(4):1006\u20131014.","journal-title":"Haematologica"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.17294\/2330-0698.1951"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01872-x"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21873"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01424-6"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-03534-8"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.18502\/ijhoscr.v19i3.19288"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2510223"},{"key":"e_1_3_5_74_1","unstructured":"Food and Drug Administration. FDA approves oral combination of decitabine and cedazuridine tablets with venetoclax for newly diagnosed acute myeloid leukemia. Food and drug administration. 2026 [cited 2026 16 June]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-oral-combination-decitabine-and-cedazuridine-tablets-venetoclax-newly-diagnosed-acute"},{"key":"e_1_3_5_75_1","unstructured":"Food and Drug Administration. Highlights of prescribing information: decitabine and cedazuridine tablets for oral use Food and drug administration. 2026 [cited 2026 Jun 16]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/0212576s008lbl.pdf"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00033-4"},{"key":"e_1_3_5_77_1","unstructured":"Food and Drug Administration. Highlights of prescribing: azacitidine tablets for oral use 2026 [cited 2026 16 June]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/214120s003lbl.pdf"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26847"},{"key":"e_1_3_5_79_1","unstructured":"Food and Drug Administration. Highlights of prescribing infromation: azacitidine tablets for oral use 2026 [cited 2026 June 29]. Available from: https:\/\/www.accessdata.fda.gov\/spl\/data\/1b026a12-462b-40f3-81d8-099c1b111718\/1b026a12-462b-40f3-81d8-099c1b111718.xml"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904544"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-621664"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.9429"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2020.11.4.2"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1188\/22.ONF.279-295"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221112603"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9030130"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15147"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2338"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae241"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30120744"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.2196\/64208"},{"issue":"7","key":"e_1_3_5_92_1","first-page":"426","article-title":"Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis","volume":"32","author":"Chow SM","year":"2024","unstructured":"Chow SM, Tan BK. Effectiveness of mHealth apps on adherence and symptoms to oral anticancer medications: a systematic review and meta-analysis. Support Care Cancer. 2024;32(7):426.","journal-title":"Support Care Cancer"},{"key":"e_1_3_5_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/OP.24.00031"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2025.2544859"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241257313"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241238979"},{"issue":"4","key":"e_1_3_5_97_1","first-page":"e128","article-title":"Provider and patient burdens of obtaining oral anticancer medications","volume":"24","author":"Geynisman DM","year":"2018","unstructured":"Geynisman DM, Meeker CR, Doyle JL, et al. Provider and patient burdens of obtaining oral anticancer medications. Am J Manag Care. 2018;24(4):e128\u2013e133.","journal-title":"Am J Manag Care"},{"key":"e_1_3_5_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22233"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.005"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-013-0032-2"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0565"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2015.08.010"},{"key":"e_1_3_5_103_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24767"},{"key":"e_1_3_5_104_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01346-1"},{"key":"e_1_3_5_105_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1160966"},{"key":"e_1_3_5_106_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0179"},{"key":"e_1_3_5_107_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145114"},{"key":"e_1_3_5_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867"},{"key":"e_1_3_5_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-026-03038-7"},{"key":"e_1_3_5_110_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473646"},{"key":"e_1_3_5_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017934"},{"key":"e_1_3_5_112_1","doi-asserted-by":"publisher","DOI":"10.33696\/haematology.7.073"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2705531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2705531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2705531","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:27:44Z","timestamp":1793618864000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2705531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":110,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"alternative-id":["10.1080\/14737140.2026.2705531"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2705531","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}